JP2022514537A5 - - Google Patents

Info

Publication number
JP2022514537A5
JP2022514537A5 JP2021534215A JP2021534215A JP2022514537A5 JP 2022514537 A5 JP2022514537 A5 JP 2022514537A5 JP 2021534215 A JP2021534215 A JP 2021534215A JP 2021534215 A JP2021534215 A JP 2021534215A JP 2022514537 A5 JP2022514537 A5 JP 2022514537A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
salcardin
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021534215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022514537A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/066003 external-priority patent/WO2020123824A1/en
Publication of JP2022514537A publication Critical patent/JP2022514537A/ja
Publication of JP2022514537A5 publication Critical patent/JP2022514537A5/ja
Pending legal-status Critical Current

Links

JP2021534215A 2018-12-13 2019-12-12 急性心房細動の処置のためのサルカルディン投与 Pending JP2022514537A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862779056P 2018-12-13 2018-12-13
US62/779,056 2018-12-13
US201962858324P 2019-06-06 2019-06-06
US62/858,324 2019-06-06
PCT/US2019/066003 WO2020123824A1 (en) 2018-12-13 2019-12-12 Sulcardine administration for treatment of acute atrial fibrillation

Publications (2)

Publication Number Publication Date
JP2022514537A JP2022514537A (ja) 2022-02-14
JP2022514537A5 true JP2022514537A5 (cg-RX-API-DMAC7.html) 2022-12-19

Family

ID=69165588

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021534215A Pending JP2022514537A (ja) 2018-12-13 2019-12-12 急性心房細動の処置のためのサルカルディン投与

Country Status (11)

Country Link
US (4) US11364223B2 (cg-RX-API-DMAC7.html)
EP (1) EP3893870A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022514537A (cg-RX-API-DMAC7.html)
KR (1) KR20210135990A (cg-RX-API-DMAC7.html)
CN (1) CN113453677A (cg-RX-API-DMAC7.html)
AU (1) AU2019397511B2 (cg-RX-API-DMAC7.html)
CA (1) CA3123078A1 (cg-RX-API-DMAC7.html)
IL (1) IL283931A (cg-RX-API-DMAC7.html)
MX (1) MX2021006933A (cg-RX-API-DMAC7.html)
WO (1) WO2020123824A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202104166B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020123824A1 (en) 2018-12-13 2020-06-18 Huya Bioscience International, Llc Sulcardine administration for treatment of acute atrial fibrillation
KR102405199B1 (ko) 2019-01-29 2022-06-02 후야 바이오사이언스 인터내셔널 엘엘씨 설카딘 염
US11813245B2 (en) * 2020-06-12 2023-11-14 Huyabio International, Llc Sulcardine administration for treatment of acute atrial fibrillation
CN114984004B (zh) * 2022-05-25 2023-09-12 扬州中宝药业股份有限公司 硫酸舒欣啶在制备抗脓毒症药物中的应用
WO2026036095A1 (en) * 2024-08-08 2026-02-12 Huyabio International, Llc J-Tp PROTECTION

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1172908C (zh) 1999-12-10 2004-10-27 中国科学院上海药物研究所 N-取代苄基或苯基芳香磺酰胺化合物及其用途
CN1939298A (zh) 2005-09-29 2007-04-04 中国科学院上海药物研究所 硫酸舒欣啶固体和靶向制剂及其制备方法
CN101484181B (zh) 2006-06-30 2012-12-26 希格马托罕见疾病公司 用于生产l-天门冬酰胺酶ⅱ的重组宿主
KR101491867B1 (ko) 2007-01-31 2015-02-10 피페넥스 인크. 증가된 발현을 위한 박테리아 리더 서열
WO2011062903A2 (en) 2009-11-17 2011-05-26 Elliott Gary T Slow infusion of sulcardine and its salts
US8541464B2 (en) * 2009-11-17 2013-09-24 HUYA Biosciences International LLC Treatment of atrial fibrillation
WO2011126811A2 (en) 2010-03-30 2011-10-13 Pfenex Inc. High level expression of recombinant toxin proteins
KR102092225B1 (ko) 2014-04-30 2020-03-23 주식회사 엘지화학 고효율 분비능을 가지는 단백질 분비 인자 및 이를 포함하는 발현 벡터
WO2016089782A1 (en) 2014-12-01 2016-06-09 Pfenex Inc. Fusion partners for peptide production
EP3302442B1 (en) 2015-06-03 2024-10-16 Triastek, Inc. Dosage forms and use thereof
AU2017261372B2 (en) 2016-05-05 2019-02-14 Triastek, Inc. Controlled release dosage form
AU2018212273B2 (en) 2017-01-26 2023-12-21 Triastek, Inc. Dosage forms of controlled release at specific gastrointestinal sites
WO2020123824A1 (en) 2018-12-13 2020-06-18 Huya Bioscience International, Llc Sulcardine administration for treatment of acute atrial fibrillation
KR102405199B1 (ko) 2019-01-29 2022-06-02 후야 바이오사이언스 인터내셔널 엘엘씨 설카딘 염

Similar Documents

Publication Publication Date Title
JP2023088944A5 (cg-RX-API-DMAC7.html)
JP2015526458A5 (cg-RX-API-DMAC7.html)
JP2024540183A5 (cg-RX-API-DMAC7.html)
JP2020529996A5 (cg-RX-API-DMAC7.html)
JP5796959B2 (ja) 関節炎における痛みの治療のためのタペンタドール
JP2009511618A (ja) 中度から重度のむずむず脚症候群(rls)を治療するためのプラミペキソールの使用
JPS60188323A (ja) 心筋虚血治療用医薬組成物
WO2009150535A1 (en) Dronedarone for the prevention of permanent atrial fibrillation
JP2021527031A5 (cg-RX-API-DMAC7.html)
JP2020533296A5 (cg-RX-API-DMAC7.html)
JP2012502047A (ja) 心房細動を治療する方法
JP2018537513A5 (cg-RX-API-DMAC7.html)
JP2015500285A5 (cg-RX-API-DMAC7.html)
JP2019529570A5 (cg-RX-API-DMAC7.html)
JP2022514537A (ja) 急性心房細動の処置のためのサルカルディン投与
JP2024531188A5 (cg-RX-API-DMAC7.html)
JP5680412B2 (ja) レオヌリンの使用およびその組成物
JP2023553253A5 (cg-RX-API-DMAC7.html)
JP2023549849A5 (cg-RX-API-DMAC7.html)
JP2020531543A5 (cg-RX-API-DMAC7.html)
JPH0232023A (ja) パーキンソン症候群の治療用薬剤
JP2019531286A5 (cg-RX-API-DMAC7.html)
WO2020067333A1 (ja) 線維症治療用医薬組成物
JP2024545496A5 (cg-RX-API-DMAC7.html)
CN113876775B (zh) 一种青藤碱或其药物可接受的盐作为治疗动脉性肺动脉高压药物的用途